Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 3
2021 2
2022 1
2024 12
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: FD-16208
Page 1
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.
Tsimberidou AM, Alayli FA, Okrah K, Drakaki A, Khalil DN, Kummar S, Khan SA, Hodi FS, Oh DY, Cabanski CR, Gautam S, Meier SL, Amouzgar M, Pfeiffer SM, Kageyama R, Yang E, Spasic M, Tetzlaff MT, Foo WC, Hollmann TJ, Li Y, Adamow M, Wong P, Moore JS, Velichko S, Chen RO, Kumar D, Bucktrout S, Ibrahim R, Dugan U, Salvador L, Hubbard-Lucey VM, O'Donnell-Tormey J, Santulli-Marotto S, Butterfield LH, Da Silva DM, Fairchild J, LaVallee TM, Padrón LJ, Sharma P. Tsimberidou AM, et al. J Exp Med. 2024 Oct 7;221(10):e20240152. doi: 10.1084/jem.20240152. Epub 2024 Aug 27. J Exp Med. 2024. PMID: 39190534 Free PMC article.
ITAM-based receptors in natural killer cells.
Aguilar OA, Fong LK, Lanier LL. Aguilar OA, et al. Immunol Rev. 2024 May;323(1):40-53. doi: 10.1111/imr.13313. Epub 2024 Feb 27. Immunol Rev. 2024. PMID: 38411263 Free PMC article. Review.
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting.
Saxena M, Marron TU, Kodysh J, Finnigan JP Jr, Onkar S, Kaminska A, Tuballes K, Guo R, Sabado RL, Meseck M, O'Donnell TJ, Sebra RP, Parekh S, Galsky MD, Blasquez A, Gimenez G, Bicak M, Cimen Bozkus C, Delbeau-Zagelbaum D, Rodriguez D, Acuna-Villaorduna A, Misiukiewicz KJ, Posner MR, Miles BA, Irie HY, Tiersten A, Doroshow DB, Wolf A, Mandeli J, Brody R, Salazar AM, Gnjatic S, Hammerbacher J, Schadt E, Friedlander P, Rubinsteyn A, Bhardwaj N. Saxena M, et al. Cancer Discov. 2025 May 2;15(5):930-947. doi: 10.1158/2159-8290.CD-24-0934. Cancer Discov. 2025. PMID: 40094414 Clinical Trial.
Natural Killer Cells and Thyroid Diseases.
Lee EK, Sunwoo JB. Lee EK, et al. Endocrinol Metab (Seoul). 2019 Jun;34(2):132-137. doi: 10.3803/EnM.2019.34.2.132. Endocrinol Metab (Seoul). 2019. PMID: 31257741 Free PMC article. Review.
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.
Galsky MD, Autio KA, Cabanski CR, Wentzel K, Graff JN, Friedlander TW, Howes TR, Shotts KM, Densmore J, Spasic M, Da Silva DM, Chen RO, Lata J, Skolnik J, Keler T, Yellin MJ, LaVallee TM, Fairchild J, Boffo S, O'Donnell-Tormey J, Dugan U, Bhardwaj N, Subudhi SK, Fong L. Galsky MD, et al. Clin Cancer Res. 2025 Apr 14;31(8):1463-1475. doi: 10.1158/1078-0432.CCR-24-3693. Clin Cancer Res. 2025. PMID: 39964352 Free PMC article. Clinical Trial.
30 results